jRCT2031210340招募中不适用
An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors
Novartis Pharma. K.K.0 个研究点目标入组 10 人开始时间: 2021年10月25日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 主要终点
- Number of patients with adverse events and serious adverse events
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Signed informed consent must be obtained prior to participation in the study.
- •Male or female patients must be >= 18 years of age.
- •Dose escalation part: patients with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma or other solid tumors. Patients with solid tumors other than mesothelioma must have local available data for loss-of-function NF2/LATS1/LATS2 genetic alterations (truncating mutation or gene deletion; LATS1/LATS2 mutations will only be included in the dose escalation part), or functional YAP/TAZ fusions. Patients with malignant EHE can be enrolled with only histological confirmation of the disease. Patients must have failed available standard therapies, be intolerant of or ineligible for standard therapy, or for whom no standard therapy exists.
- •Dose expansion part: the following patients will be enrolled into 3 different treatment groups:
- •Group 1: Advanced (unresectable or metastatic) MPM patients who have failed available standard therapies for advanced/metastatic disease, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
- •Group 2: Advanced (unresectable or metastatic) solid tumor patients with available local data for NF2 truncating mutation or deletions. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
- •Group 3: Advanced (unresectable or metastatic) solid tumor patients with available local data for functional YAP/TAZ fusions. EHE patients can be included with only histological confirmation of the disease. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
- •Presence of at least one measurable lesion according to mRECIST v1.1 for mesothelioma patients, RECIST v1.1 for patients with other solid tumors, or RANO for patients with primary brain tumors.
- •Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study.
排除标准
- •Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:
- •a. =< 4 weeks for thoracic radiotherapy to lung fields or limited field radiation for palliation within =< 2 weeks prior to the first dose of study treatment. An exception to this exists for patients who have received palliative radiotherapy to bone, who must have recovered from radiotherapy-related toxicities but for whom a 2-week washout period is not required.
- •b. =< 4 weeks or =< 5 half-lives (whichever is shorter) for chemotherapy or biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent.
- •c. =< 6 weeks for cytotoxic agents with risk of major delayed toxicities, such as nitrosoureas and mitomycin C.
- •d. =< 4 weeks for immuno-oncologic therapy, such as CTLA4, PD-1, or PD-L1 antagonists
- •For mesothelioma patients: use of non-invasive antineoplastic therapy (e.g., tumor treating fields, brand name Optune LuaTM) within 2 weeks of the tumor assessment at screening.
- •Malignant disease, other than that being treated in this study.
- •Insufficient renal function at Screening.
- •Clinically significant cardiac disease or risk factors at screening
- •Insufficient bone marrow function at screening.
- •Insufficient hepatic function at screening.
- •Patients who have the following laboratory values outside of the laboratory normal limits:
- •a. Potassium
- •b. Magnesium
- •c. Total calcium (corrected for low serum albumin)
- •Known active COVID-19 infection.
- •Pregnant or nursing (lactating) women,
- •Japan only: patients with a history of drug- and/or non-drug-induced interstitial lung disease (ILD) >= Grade 2.
结局指标
主要结局
Number of patients with adverse events and serious adverse events
时间窗: 3 years
Safety and tolerability of IAG933
Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only)
时间窗: 1 year
Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933
Number of patients with dose interruptions and dose changes
时间窗: 3 years
Tolerability of IAG933
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Phase 3 study of AJG533 in patients with chronic constipatioChronic constipationJPRN-jRCT2080223008EA Pharma Co.,Ltd.120
招募中
不适用
Phase I study of MGY825 in patients with advanced non-small cell lung cancerjRCT2031220278Novartis Pharma. K.K.12
未知
1 期
Phase I study of GC33 in patients with Advanced Hepatocellular Carcinoma (HCC)JPRN-jRCT2080221218Chugai Pharmaceutical Co., Ltd.18
未知
3 期
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitisJPRN-jRCT2080222653EA Pharma Co.,Ltd.120
已完成
3 期
Phase III study of AJM300 in patients with active ulcerative colitis (2)Active Ulcerative ColitisJPRN-jRCT2080223867EA Pharma Co., Ltd.198